FILAMENT HEALTH ANNOUNCES TRANSITION FROM OTCQB TO OTC PINK LIMITED

VANCOUVER, BC, May 27, 2025 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced that its common shares will shift from the OTCQB Venture Market to the OTC Pink Limited Information tier, effective prior to market open on May 28, 2025. In addition, the listing on the Frankfurt Stock Exchange has terminated.

This transition is related to Filament's decision to voluntarily delist from the Cboe Canada Exchange due to low trading volume and as part of a broader initiative to reduce operating costs and conserve capital. The Company remains committed to advancing its clinical development platform, and to its overall mission of seeing safe, natural psychedelics in the hands of everyone who needs them, as soon as possible.

Filament will continue to meet its disclosure obligations with the applicable securities regulators and will maintain current information on the OTC Markets platform.

ABOUT FILAMENT HEALTH (OTCQB:FLHLF)
Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament's platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates.

Learn more at www.filament.health and on Twitter, Instagram, and LinkedIn.

FORWARD LOOKING INFORMATION
Certain statements and information contained herein may constitute "forward‐looking statements" and "forward‐looking information," respectively, under Canadian securities legislation. Generally, forward‐looking information can be identified by the use of forward‐looking terminology such as, "expect", "anticipate", "continue", "estimate", "may", "will", "should", "believe", "intends", "forecast", "plans", "guidance" and similar expressions are intended to identify forward‐looking statements or information. The forward‐looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward‐looking statements. Forward‐looking statements regarding the Company are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such forward‐looking statements or forward‐looking information. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward‐ looking statements and forward‐looking information. Filament will not update any forward‐ looking statements or forward‐looking information that are incorporated by reference herein, except as required by applicable securities laws.

SOURCE Filament Health Corp.

INVESTOR RELATIONS: [email protected]; MEDIA RELATIONS, [email protected]